Study drug for advanced EGFR-positive solid tumors
Part of Cancer clinical trials.
This early-phase trial tests a new drug (ZZ06) in adults with advanced solid cancers that have an EGFR “positive” tumor test result. It’s for people whose cancer has grown despite standard treatment or who don’t have a standard option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have an advanced solid tumor with an EGFR-positive test, and it has progressed or there’s no standard treatment.
- You can provide stored tumor tissue from the past to confirm EGFR status with an approved test.
- You have at least one measurable cancer spot on scans.
- Your overall strength is good (performance status 0 or 1), and you’re expected to live at least 12 weeks.
- Your blood counts and organ tests (bone marrow, kidney, liver, and blood clotting) are within required ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called ACE2016 for people with advanced solid tumors that have EGFR on their surface. It may be an option if you have tried at least two other treatments (including a targeted therapy) and your cancer is still growing.
This trial tests a new drug called ZE94-0605 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and can shrink tumors.
This Phase 1/2 trial studies ZGGS18, a new medicine, in people with advanced solid tumors that either no longer respond to standard treatment or for whom standard treatment isn’t an option. The goal is to see how the drug works and what side effects it causes.
This trial is testing a new combination of two drugs (ZGGS18 and ZG005) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
This trial tests a new oral drug (ZX-8177) for people with advanced solid tumors that have stopped responding to standard treatments or cannot be treated with standard options. The goal is to see if it is safe and helps control the disease.
This study tests a new drug called JY016 for people with advanced solid tumors that have a protein called EGFR on their surface. The drug aims to help the immune system attack the cancer cells. It may be an option if standard treatments have stopped working or aren't suitable.
Hear when a new Advanced EGFR Positive Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.